One Lesson Of The OND Reorg: It Is Hard To Classify Diseases
Executive Summary
One goal of proposed overhaul of US FDA’s Office of New Drugs is creating more logical alignment of related diseases within divisions and offices. That is easier said than done.
You may also be interested in...
Value-Based Drug Reviews? US FDA Guidance Emphasizes “Accountability, Communication & Consistency”
Updated Good Review Management Principles focus exclusively on “fundamental values and operational principles” underpinning the new drug review process – leaving nuts-and-bolts procedures to be spelled out elsewhere.
Avoiding ‘Groundhog Day’: US FDA’s Biosimilar Action Plan Applies Lessons From Generic Competition
“We’re not going to wait a decade or more for robust biosimilar competition to emerge,” Commissioner Scott Gottlieb says, noting reference biologic sponsors are repeating some of the delay tactics honed in the small molecule space to keep competition at bay.
Avoiding ‘Groundhog Day’: US FDA’s Biosimilar Action Plan Applies Lessons From Generic Competition
“We’re not going to wait a decade or more for robust biosimilar competition to emerge,” Commissioner Scott Gottlieb says, noting reference biologic sponsors are repeating some of the delay tactics honed in the small molecule space to keep competition at bay.